Literature DB >> 27194722

Glucagon actions on the kidney revisited: possible role in potassium homeostasis.

Lise Bankir1, Nadine Bouby2, Bertrand Blondeau3, Gilles Crambert3.   

Abstract

It is now recognized that the metabolic disorders observed in diabetes are not, or not only due to the lack of insulin or insulin resistance, but also to elevated glucagon secretion. Accordingly, selective glucagon receptor antagonists are now proposed as a novel strategy for the treatment of diabetes. However, besides its metabolic actions, glucagon also influences kidney function. The glucagon receptor is expressed in the thick ascending limb, distal tubule, and collecting duct, and glucagon regulates the transepithelial transport of several solutes in these nephron segments. Moreover, it also influences solute transport in the proximal tubule, possibly by an indirect mechanism. This review summarizes the knowledge accumulated over the last 30 years about the influence of glucagon on the renal handling of electrolytes and urea. It also describes a possible novel role of glucagon in the short-term regulation of potassium homeostasis. Several original findings suggest that pancreatic α-cells may express a "potassium sensor" sensitive to changes in plasma K concentration and could respond by adapting glucagon secretion that, in turn, would regulate urinary K excretion. By their combined actions, glucagon and insulin, working in a combinatory mode, could ensure an independent regulation of both plasma glucose and plasma K concentrations. The results and hypotheses reviewed here suggest that the use of glucagon receptor antagonists for the treatment of diabetes should take into account their potential consequences on electrolyte handling by the kidney.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  cAMP; calcium; electrolytes; gluconeogenesis; membrane receptor; sodium

Mesh:

Substances:

Year:  2016        PMID: 27194722     DOI: 10.1152/ajprenal.00560.2015

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  6 in total

1.  Renal potassium handling in carriers of the Gly40Ser mutation of the glucagon receptor suggests a role for glucagon in potassium homeostasis.

Authors:  Lise Bankir; Antonio Barbato; Ornella Russo; Gilles Crambert; Roberto Iacone; Nadine Bouby; Ludovica Perna; Pasquale Strazzullo
Journal:  Physiol Rep       Date:  2018-04

Review 2.  Mineral and Electrolyte Disorders With SGLT2i Therapy.

Authors:  Giuseppe Cianciolo; Antonio De Pascalis; Irene Capelli; Lorenzo Gasperoni; Luca Di Lullo; Antonio Bellasi; Gaetano La Manna
Journal:  JBMR Plus       Date:  2019-11-04

Review 3.  Hyperkalemia in Diabetes Mellitus Setting.

Authors:  Kleber Goia-Nishide; Lucas Coregliano-Ring; Érika Bevilaqua Rangel
Journal:  Diseases       Date:  2022-03-28

Review 4.  The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture.

Authors:  Bingzi Dong; Ruolin Lv; Jun Wang; Lin Che; Zhongchao Wang; Zhouyang Huai; Yangang Wang; Lili Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-07       Impact factor: 6.055

5.  Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.

Authors:  Victoria E R Parker; Thuong Hoang; Heike Schlichthaar; Fraser W Gibb; Barbara Wenzel; Maximillian G Posch; Ludger Rose; Yi-Ting Chang; Marcella Petrone; Lars Hansen; Philip Ambery; Lutz Jermutus; Hiddo J L Heerspink; Rory J McCrimmon
Journal:  Diabetes Obes Metab       Date:  2022-04-25       Impact factor: 6.408

6.  SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients.

Authors:  Evan C Ray; Cary R Boyd-Shiwarski; Pengfei Liu; Danica Novacic; David Cassiman
Journal:  Kidney Med       Date:  2020-04-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.